2-(4-chloro-2-methylphenoxy)-N-[2-(trifluoromethyl)phenyl]propanamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-chloro-2-methylphenoxy)-N-[2-(trifluoromethyl)phenyl]propanamide
• 化学式: C₁₇H₁₅ClF₃NO₂
• 分子量: 357.8
• InChiKey: NYEUXEWXWIOAAX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Pharmaceutical use of substituted amides
  申请人：Andersen Sune Henrik

  公开号：US20060111366A1

  公开（公告）日：2006-05-25

  The use of substituted amides for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11βHSD1 and may be useful in the treatment, prevention and/or prophylaxis of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.

  本文介绍了使用取代酰胺来调节11β-羟化甾体脱氢酶1型（11βHSD1）的活性以及将这些化合物用作制药组合物的方法。还介绍了一类新型的取代酰胺，它们在治疗中的应用、包含这些化合物的制药组合物以及它们在药物制剂制造中的应用。这些化合物是11βHSD1的调节剂，更具体地说是抑制剂，可用于治疗、预防和/或预防一系列需要降低活性糖皮质激素细胞内浓度的医学疾病。
• Amide Derivatives and Pharmaceutical Use Thereof
  申请人：Andersen Henrik Sune

  公开号：US20090264414A1

  公开（公告）日：2009-10-22

  The use of substituted amides for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11βHSD1 and may be useful in the treatment, prevention and/or prophylaxis of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.

  本文描述了使用取代酰胺来调节11β-羟化类固醇脱氢酶1型（11βHSD1）活性以及这些化合物作为药物组分的用途。还描述了一类新型的取代酰胺，它们在治疗中的用途，包括含有这些化合物的药物组分以及它们在制造药物中的用途。这些化合物是调节剂，更具体地说是11βHSD1活性的抑制剂，可用于治疗、预防和/或预防一系列医学疾病，其中降低细胞内活性糖皮质激素的浓度是可取的。
• A new herbicidal composition, processes for its production and its use
  申请人：A. Nattermann & Cie. GmbH

  公开号：EP0068295A1

  公开（公告）日：1983-01-05

  The invention relates to new herbicidal compositions consisting of one or more herbicidally active substances and one or more certain phospholipides in addition to standard vehicles, diluents, solvents and/or other inert auxiliaries, the ratio by weight of the herbicidally active substance or mixture of herbicidally active substances to pure phospholipide or to the mixture of pure phospholipides amounting to between 1 : 0.2 and 1 : 20. The Invention also relates to processes for producing these compositions and to processes for controlling weeds and wild grasses using the new herbicidal compositions.

  本发明涉及新的除草组合物，除标准载体、稀释剂、溶剂和/或其它惰性助剂外，还包括一种或多种除草活性物质和一种或多种特定磷脂，除草活性物质或除草活性物质混合物与纯磷脂或纯磷脂混合物的重量比在 1 : 0.本发明还涉及生产这些组合物的工艺和使用新除草组合物控制杂草和野草的工艺。
• Use of membrane modulators and products comprising such membrane modulators
  申请人：A. Nattermann & Cie. GmbH

  公开号：EP0231765A1

  公开（公告）日：1987-08-12

  The invention is related to the use of certain water-soluble compounds known as such and having the Formula forthe modulation of membrane dependent metabolism processes within living cells, in particular with relation to transport phenomena and cell procedures which are induced or influenced by active agents supplied from outside the cell, products containing these substances for the above described uses and processes using these products.

  本发明涉及某些已知的水溶性化合物的用途，这些化合物具有调节活细胞内膜依赖性新陈代谢过程的配方，特别是与细胞外活性剂诱导或影响的运输现象和细胞程序有关的配方，以及含有这些物质的用于上述用途的产品和使用这些产品的工艺。
• Combinations of an 11-beta-hydroxysteroid dehaydrogenase type 1 inhibitor and a glucocorticoid receptor agonist
  申请人：NOVO NORDISK A/S

  公开号：EP1854487A2

  公开（公告）日：2007-11-14

  Combination therapy comprising the administration of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist for treating some forms of cancer, diseases and disorders having inflammation as a component, and to minimize the side effects associated with glucorticoid receptor agonist therapy.

  由 11β- 羟类固醇脱氢酶 1 型抑制剂和糖皮质激素受体激动剂组成的联合疗法，用于治疗某些形式的癌症、以炎症为组成部分的疾病和失调，并最大限度地减少与糖皮质激素受体激动剂疗法相关的副作用。